Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection
NCT ID: NCT02306564
Last Updated: 2016-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
150 participants
INTERVENTIONAL
2014-12-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All women included in the study, after applying eligibility criteria , will be subjected to careful history taking and general and local examination, follicle stimulating hormone (FSH), luteinizing hormone (LH), Antral follicle count (AFC) \&Antimullerian hormone (AMH) will be recorded and body mass index (BMI) calculation is done.
BMI is defined as weight in kilograms divided by height in meters squared (kg/m2), Excess weight is BMI ≥ 25 kg/m2 and obesity is BMI ≥ 30 kg/m2.
As most patients needing cabergoline for prevention of hyperstimulation are obese, therefore only those with BMI ≥ 30 kg/m2 will be included in the study. The study will include three groups, each group containing 50 patients.
Group A will include patients at risk of OHSS receiving Cabergoline 0.5mg daily for 8 days (Dostinex®, Pfizer Australia Pty Ltd ) from the day of oocyte pick up for prevention of hyperstimulation. Group B will include patients at risk of ovarian hyperstimulation syndrome (OHSS) not receiving Cabergoline. While group C will serve as a control group and will include age \& BMI matched patients not at risk of OHSS, and not receiving cabergoline.
Risk of developing ovarian hyperstimulation syndrome (OHSS) and expectation of high oocyte yield will include serum E2\>3,500 pg/ml and more than 20 follicles ≥11 mm on the day of final oocyte maturation, \& Patients who underwent coasting for OHSS prevention.
The standard long gonadotrophin-releasing hormone (GnRH) agonist protocol will be used for patients with predicted normal response based on clinical \& hormonal profile ; 1 mg of leuprolide acetate daily subcutaneous injection (s.c) (Lucrin ®; Abbott, Hoofddorp, The Netherlands) is applied from the mid luteal phase onward till the day of HCG injection.
Gonadotropins in the form of human menopausal gonadotropin (HMG) (Merional ®, IBSA, Institute Biochimique SA, Lugano, Switzerland) will be given by intramuscular injection (IM) from the 2nd day of menstruation after confirmed down regulation (E2\<50pg/ml), The starting dose range from 150 to 300 IU depending on the basal FSH level, AFC, maternal age and BMI.
Patients with high predicted high response as evidenced by high serum AMH (more 4.0 ng/ml), or inverted FSH:LH ratio (polycystic ovarian syndrome PCOS) or, high antral follicle count (over 30) will be given Antagonist protocol where human menopausal gonadotropin (HMG) (Merional ®, IBSA, Institute Biochimique SA, Lugano, Switzerland) will be given IM from the 2nd day of menstruation, The starting dose range from 150 to 300 IU and Gnrh Antagonist cetrorelix acetate (Cetrotide®, Zentaris IVF GmbH, Australia), 0.25 mg S.C, onwards will be given daily when the lead follicle reaches 14mm.
In all protocols, stimulation is monitored by trans-vaginal ultrasonography and serial E2 measurements starting from day 7 of the cycle and the gonadotropin dose is adjusted individually according to follicular response.
After the development of at least three leading follicles≥18 mm, 10,000 unit of HCG (Choriomon, IBSA, Institute Biochimique SA) is given IM, and a trans vaginal ultrasound-guided oocyte retrieval is performed 36 hours later.
Patients with expected high oocyte yield, will be sent on the last day of folliculometry to do three dimensional (3D) power Doppler to determine endometrial vascularity.
After ovum pick up, Oocytes are then fertilized in vitro using ICSI and after three to five days embryo transfer will be done using labotec catheter (Labotec, Gottingen Germany) with ultrasound guidance.
A second Trans-vaginal U/S demonstrating endometrial vascularity will be done 1 hour before embryo-transfer.
Progesterone pessaries 400 mg twice daily (Cyclogest 400mg ®Actavis plc. Dublin, Ireland) is given as a luteal support starting from the day of embryo transfer and continued for 16 days after.
Pregnancy is defined as the occurrence of a positive beta human chorionic gonadotrophin (βHCG) \>10 IU on day 12 after embryo transfer and a second higher value 2 days later, followed by ultrasonography confirmation of cardiac activity at 6 weeks gestation.
The criteria for cycle cancellation are:
* The presence of less than three follicles.
* E2 level less than500 pg/ml.
All 3D ultrasound and power Doppler examinations will be carried out by one investigator on the day of final oocyte maturation and repeated again on the day of embryo transfer, 1 hour before the procedure.
The Voluson 730 machine (GE Healthcare Austria GmbH, Seoul, Korea) with an endocavitary volumetric 4-9MHz vaginal probe after bladder evacuation, Computer-Aided Analysis (VOCAL™) Imaging Program for the 3D power Doppler histogram analysis will be used to measure the endometrial volume (EV) and 3D power Doppler indices within the endometrium .
Vascularization index (VI) measures the ratio of the number of color voxels to the total number of voxels (%) and represents the presence of blood vessels (vascularity). Flow index (FI) measures the mean power Doppler signal intensity (0-100) and represents the average intensity of blood flow. Vascularization flow index (VFI) is calculated by multiplying VI and FI (0-100) and represents a combination of vascularity and flow intensity
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Group A will include patients at risk of OHSS receiving Cabergoline 0.5mg daily for 8 days (Dostinex®, Pfizer Australia Pty Ltd ) from the day of oocyte pick up for prevention of hyperstimulation
Cabergoline
given to patients at high risk for OHSS
Group B
Group B will include patients AT RISK of ovarian hyperstimulation syndrome (OHSS) not receiving Cabergoline.
No interventions assigned to this group
Group C
Group C will serve as a control group and will include age \& BMI matched patients NOT AT RISK of OHSS, and not receiving cabergoline.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cabergoline
given to patients at high risk for OHSS
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Normal serum prolactin level.
3. Tubal factor of infertility.
4. Unexplained infertility.
5. BMI ≥ 30 kg/m2.
6. Estradiol (E2)\>3,500 pg/ml on day of ovulation trigger.
7. Patients who underwent coasting for OHSS prevention.
8. More than 20 follicles ≥11 mm on the day of final oocyte maturation.
Exclusion Criteria
2. Severe Male factor infertility.
3. Hyperprolactinemic patients.
4. Frozen embryo transfer cycles
5. Uterine Anomalies.
6. Uterine synechia.
7. History of Genital Tuberculosis.
8. Repeated implantation failure in ICSI.
9. On medication that is known to alter prolactin levels e.g antipsychotics, Atypical agents and risperidone
10. Thyroid dysfunction.
11. Medical disorders affecting serum prolactin eg acromegaly ,chronic renal failure and hypothyroidism
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kasr El Aini Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed M.Kamel
Lecturer of Obstetric & Gynecology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed M Kamel, MD
Role: PRINCIPAL_INVESTIGATOR
Lecturer of obstetrics & Gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assissted reproduction unit Kasr alaini hospital
Ḩadā’iq al Qubbah, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Tang H, Mourad SM, Wang A, Zhai SD, Hart RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2021 Apr 14;4(4):CD008605. doi: 10.1002/14651858.CD008605.pub4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A14022014
Identifier Type: -
Identifier Source: org_study_id